
WilmerHale Reps Eleven Biotherapeutics in License Agreement with Roche for Antagonist Antibody Technology

AUGUST 17, 2016

WilmerHale represented Eleven Biotherapeutics, a biopharmaceutical company researching and developing protein therapeutics to treat diseases of the eye, in the negotiation of a license agreement with Roche for Eleven's IL-6 antagonist monoclonal antibody program, including its preclinical ophthalmic drug EBI-031.

The agreement was signed in June; its effectiveness is subject to approval by Eleven's stockholders. Assuming such approval is obtained, Eleven would be entitled to a \$7.5 million upfront, and up to \$262.5 million in future milestone, plus royalties.

The WilmerHale team consisted of Partner [Belinda Juran](#) and Associates [Alex Civetta](#) and [Ritu Gupta](#) on the license agreement, and Partners [Brian Johnson](#) and [Hal Leibowitz](#) and Counsel [Chris Barnstable-Brown](#) leading the corporate matters.

Read [Eleven Biotherapeutics' press release](#) for more information.